Valneva : Un S1 impacté par la COVID-19, une guidance 2020 ajustée à la hausse
>Un S1 fortement impacté par la COVID-19 - Valneva publie ce matin ses résultats du S1 qui se révèlent, comme attendu, fortement impactés par un effet COVID-19. Le chiffre d’affaires ressort à 47.9 M€ sur la période (vs 51.6 M€ att). A l’instar de Sanofi il y a quelques jours, les ventes du vaccin du voyageur ont été significativement ralenties durant la période. Ixiaro ressort à seulement 28.4 M€ lors de ce S1 2020 vs 30.2 M€ att en baisse de 38% à tcc. Le nouvel app...Valneva, together with its subsidiaries, is focused on vaccine development and antibody discovery. Co. generates revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®/JESPECT®), commercial partnerships around a portfolio of product candidates and licensed technology platforms (EB66® cell line, VIVA,Screen antibody discovery technology, and the IC31® adjuvant) developed by Co. Related business activities include product research and development, regulatory and clinical activities, manufacturing of commercial product and advanced clinical product candidates, as well as administrative, corporate development, and marketing and sales activities.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.